Boehringer Ingelheim Articles
Cipla patents Triomune in South Africa
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
GSK and BI license SA's Thembalami to make ARVs
19 July 2004
BI's Micardis provides sustained BP control
28 June 2004
US seniors' group sues pharma over imports
21 June 2004
Xcellsyz licensing deal with Boeh Ing
14 June 2004
SSP to sell Rx business
7 June 2004
Weak core products sales at Yamanouchi
31 May 2004
Pharma acts on US fast- track plan for FDCs
24 May 2004
Advancis Pharma names Barry Hafkin CSO
19 April 2004
Boeh Ingelheim to expand sales force
12 April 2004
Currencies hit Boeh Ingelheim results
5 April 2004
Positive EU opinion for Lilly/BI's duloxetine
5 April 2004
Boehringer Ingelheim to remain independent
22 March 2004
Boeh Ing invests 8M euros in Spain
22 March 2004
Astex and Boehringer Ingelheim form alliance
15 March 2004
Gene Logic sets up UK subsidiary
15 March 2004
Boehringer Ingelheim and Micromet sign deal
1 March 2004
Morphochem and BI enter collaboration
9 February 2004
BI's Spiriva cleared for COPD by FDA
9 February 2004
Thomas Heil to take over top job at Nippon Boehringer Ingelheim
15 December 2003
GSK, BI agree generics for South Africa
15 December 2003
S African competition ruling "inconsistent"
3 November 2003
Promising preclinical findings for MorphoSys' antibodies
27 October 2003
Chiron settles tobramycin patent dispute with Roxane
20 October 2003
Thailand gives Myanmar HIV/AIDS drug cocktail
13 October 2003
Abbott, Boehringer Ingelheim donate to beat MTCT of HIV
6 October 2003
LDCs urged over voluntary licenses
29 September 2003
German drug industry investment stays high despite reform
29 September 2003
Boeh Ing implores Germany to rewaed innovation after $285M R&D expansion
29 September 2003
Boeh Ingelheim opens new 255M-euro facility
22 September 2003
Boeh-Ing investment
22 September 2003
Fritz Sacher becomes director of Merck KGaA's MSM unit
15 September 2003
S Africa "may ban nevirapine for MTCT"
11 August 2003
German management now moving to USA
11 August 2003
BI hit by costs and currencies in first half
11 August 2003
Medivir and Boehringer Ingelheim sign antiviral deal
21 July 2003
Majors rush to roll out new drugs in Japan
14 July 2003
Errata: Flomox/Flomax
16 June 2003
Mead Johnson to acquire Cafcit
12 May 2003
Boehringer Ingelheim gets CRM implementation award
21 April 2003
Poor take-up for Cipla HIV/AIDS cocktail
31 March 2003
BI breaks ground on new Austrian site
31 March 2003
S African rape victim may sue over drugs
24 March 2003
Dundee Univ $24.5 M deal with six drug majors
24 March 2003
Boeh Ingelheim and SSP expand alliance
17 March 2003
Pharmagene sees 12% hike in 2002 sales
17 March 2003
Boeh Ingelheim's tipranavir for PI resistance
24 February 2003
Viramune as good as more costly Sustiva
24 February 2003
Boeh Ingelheim starts two mega-trials
24 February 2003
S African Minister
17 February 2003
Central American HIV/ AIDS drug prices cut
10 February 2003
Actilyse gets stroke indication in EU
3 February 2003
China to make four HIV/ AIDS drugs from Jan
13 January 2003
Bayer to co-market BI's telmisartan
19 August 2002
Boehringer Ingelheim's operating income up 48% in first half; Spiriva prospects strong
19 August 2002
Anglo American first to give employees free AIDS treatments
12 August 2002
Plea for SA activist to take AIDS drugs
12 August 2002
Mandela "to talk to Mbeki about antiretrovirals"
5 August 2002
WHO OKs Ranbaxy HIV/AIDS generics
29 July 2002
Lessons of ECJ verdicts on PI repackaging
29 July 2002
S African province offers antiretrovirals
29 July 2002
Viramune MTCT study has arm stopped early
22 July 2002
S Africa must supply nevirapine, court rules
15 July 2002
GPC, Boehringer make progress against HPV
15 July 2002
Nippon BI's new medical teams
15 July 2002
Caribbean/pharma HIV cut-price drug deal
15 July 2002
Boehringer's tipranavir effective in resistant HIV
15 July 2002
Spiriva launched in first markets
10 June 2002
First shipment of BI's nevirapine for Kenya
3 June 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
Thai/African HIV/AIDS generic drug deals
27 May 2002
Improvements for GPC Biotech's 1st qtr
27 May 2002
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
